Senseonics SENS recently announced the European launch of its groundbreaking Eversense 365 CGM system, the world’s first ...

Is DXCM a good stock to buy? We came across a bullish thesis on DexCom, Inc. on Part-Time Compounder’s Substack by Francesco ...

DexCom's Q1 results may see strong growth from G7 uptake and CGM demand, but pricing mix and rising investments could weigh on margins.

Detailed price information for Senseonics Holdings Inc (SENS-Q) from The Globe and Mail including charting and trades.

A major clinical trial has found that real-time continuous glucose monitoring (CGM) significantly improves blood glucose ...

Apple Watch displays real-time glucose data from CGM devices like the Dexcom G7, while Apple continues to develop ...

Dexcom G7 CGMs contain a complex electronic assembly within a wearable package that stands up to the rigors of everyday ...

The multi-billion dollar CGM market is expected to experience substantial, double-digit percentage growth over the next five ...

Senseonics VP of Product Development Hari Sree explains the tech behind the Eversense 365-day CGM and what’s next in the ...

ETHealthworld.com brings latest blood glucose levels news, views and updates from all top sources for the Indian Health industry.

DexCom's expanding CGM market, G7 rollout, and global growth momentum position it for gains, despite pricing pressure and ...

BARCELONA, Spain--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, will present new findings that showcase the benefits of its glucose biosensing technology for ...